ASSESSMENT OF SERUM LEVELS OF THE ADIPOCYTOKINE CHEMERIN IN COLORECTAL CANCER PATIENTS

UTVRĐIVANJE NIVOA ADIPOCITOKINA KEMERINA U SERUMU KOD OBOLELIH OD KOLOREKTALNOG KARCINOMA

Manal M. Alkady, Phebe L. Abdel-Messeih, Neveen M. Nosseir

Radiation Health Research Department, National Center for Radiation Research and Technology, Atomic Energy Authority, Cairo, Egypt

Summary

Background: Colorectal cancer (CRC) is one of the most common cancers worldwide. The tumor microenvironment is very important for determining cancer cell growth and spreading. Chemerin, a newly identified adipokine secreted by adipose tissue, is known to be associated with obesity, metabolic syndrome, and insulin resistance. The present study was carried out to investigate the association between serum levels of chemerin and colorectal cancer.

Methods: Thirty-two patients with colorectal cancer aged 57.6±6.5 years, and twenty age, sex and BMI matched healthy controls were included in the study. Serum chemerin levels were determined using enzyme linked immunosorbent assay. C-reactive protein (CRP) levels were determined using a turbidimetric immunoassay. Carcino embryonic antigen (CEA) and carbohydrate antigen (CA 19-9) were measured by radioimmunoassay.

Results: Chemerin levels were found to be significantly higher in patients relative to the controls (P<0.001) and gradually increased with the TNM tumor stage progression. The mean CRP, CEA and CA 19-9 levels were also significantly higher in patients (P<0.001). There was a significant correlation between the serum levels of chemerin and the other measured parameters in CRC patients. The area under receiver operating characteristic curve (ROC) for serum chemerin was 1 at a cut-off value ≥ 161.5 with 100% sensitivity and 100% specificity.

Kratak sadržaj

Uvod: Kolorektalni karcinom (KRK) jedan je od najčešćih oblika karcinoma širom sveta. Mikrokolinija tumora veoma je važna za procenu rasta i širenja celija kancer. Kemerin je nedavno identifikovan adipokin koji se izlučuje iz adipoznog tkiva i utvrđeno je da je povezan sa gojaznošću, metaboličkim sindromom i insulinom rezistencijom. Ova studija sprovedena je kako bi se ispitala povezanost između nivoa kemerina u serumu i kolorektalnog karcinoma.

Metode: U studiju je uključeno 32 pacijenta sa kolorektalnim karcinomom starosti 57,6±6,5 godina i 20 zdravih kontrolnih osoba odgovarajuće starosti, pola i indeksa telesne mase (ITM). Nivoi kemerina u serumu određeni su pomoću ELISA testa. Nivoi C-reaktivnog proteina (CRP) određeni su pomoću turbidimetrijskog imunoodređivanja. Karcinoembrioni antigen (CEA) i ugljenohidratni antigen (CA19-9) mereni su radioimmunooodređivanjem.

Rezultati: Nivoi kemerina bili su znaczajno viši kod obolelih u odnosu na kontrolne osobe (P<0,01) i postepeno su rašli za jedno sa stepenima tumorske skale TNM. Srednji nivoi CRP, CEA i CA 19-9 bili su takođe znaczajno viši kod obolelih (P<0,001). Pronađena je znaczajna korelacija između nivoa kemerina u serumu i ostalih merenih parametara kod obolelih od KRK-a. Površina ispod ROC krive za kemerin u serumu bila je 1 pri cutoff vrednosti ≥ 161,5, uz osjetljivost od 100% i specifičnost od 100%.

List of abbreviations: Carbohydrate antigen (CA 19-9); carcinoembryonic antigen (CEA); C-reactive protein (CRP); tumor necrosis factor alpha (TNF-α); vascular cell adhesion molecule-1 (VCAM-1); MMP-7, matrix metalloproteinase-7; ERK1/2, extracellular signal-regulated kinase.
Conclusions: The observed results suggest that chemerin may have a potential role in the pathogenesis and progression of colorectal malignancy and may be a good biomarker of colorectal cancer and stage progression.

Keywords: colorectal cancer, chemerin, C-reactive protein, carcinoembryonic antigen

Introduction

Colorectal cancer (CRC) is the third most commonly diagnosed malignancy and the fourth leading cause of cancer death in the world, accounting for about 1.4 million new cases and almost 700,000 deaths in 2012 (1). In Egypt, GLOBOCAN 2012 showed that colorectal cancer is considered the 8th cancer after breast, liver, non-Hodgkin lymphoma, brain, ovary, leukemia and bladder cancer with an incidence rate accounting for 4% and 3.5% for men and women respectively.

The association between obesity and human malignancies including colorectal cancer (CRC) has been increasingly recognized, but the underlying biological mechanisms are not fully understood. Chronic inflammation, insulin resistance and adipocytokines are contributing factors (2–4).

Adipokines are polypeptide cytokines produced by white adipose tissue, acting not only as local paracrine signaling cytokines, but also at distant levels, through secretion in the circulation (5). In obesity, the hypertrophic expansion of adipose tissue induces local hypoxia, inflammatory activation and reactive angiogenesis, changes which favor tumorigenesis (6). More than 15 adipokines have been reported to be associated with cancers (7). While the circulating levels of proinflammatory adipokines, such as leptin, IL-6 and tumor necrosis factor alpha (TNF-α), are increased in cancers, some others such as adiponectin are protective against tumorigenesis and its serum levels are usually decreased in the patients with cancer (8).

Chemerin is a novel adipokine, which plays an important role in adipogenesis and chemotaxis of the innate immune system (9). Chemerin and its major receptor, CMKLR1, are expressed in white adipose tissue, and circulating levels of this adipokine are elevated in obesity and metabolic syndrome (10). It may link obesity and inflammation since chemerin is a proinflammatory cytokine that recruits and activates immune cells and contributes to inflammation by promoting macrophage adhesion to vascular cell adhesion molecule-1 (VCAM-1) and fibronectin (11). The association of chemerin and cancer is not yet fully understood. Chemerin promotes angiogenesis via inducing matrix metalloproteinase secretion and activity. Therefore, it is thought that high levels of chemerin may have an initiating role in a further process; carcinogenesis, then metastasis (12). Otherwise, chemerin was demonstrated to recruit natural killer cells which are suggested to play a great role in antitumor defense (13). So, in this study we aimed to evaluate the serum levels of chemerin in colorectal cancer patients to understand the possible role of adipocytokines in relation to CRC development and progression.

Subjects and Methods

This is a case-control study including thirty-two patients attending the gastrointestinal endoscopy unit of the tropical medicine department, Kasr El Aini hospital, Faculty of Medicine, Cairo University. All had been diagnosed with CRC after colonoscopy, aged 57.6±6.5 years. Exclusion criteria: no curative medication for CRC; no previous history of malignancy or colorectal operations; no diagnosis of familial adenomatous polyposis or acromegaly; no diagnosis of any inflammatory bowel disease, including ulcerative colitis and Crohn’s disease; patients with diabetes mellitus, chronic liver and kidney diseases were excluded. Twenty healthy subjects of comparable age and sex and BMI served as a control group.

All procedures were performed according to the ethical standards of the institutional and national research committee given in the Declaration of Helsinki 1964, as revised in 2013. A written informed consent of participation in the study was taken from all participants. This study was approved by the Committee of Ethics and Research of the university hospital.

Fasting blood samples were collected from all subjects in blank vacutainers, left to clot, centrifuged and the sera were separated and stored at –20°C till assay date.

Biochemical analysis:

- Fasting blood sugar was measured by glucose oxidase method (Beckman Glucose Analyzer, Fullerton, CA, USA)
- Serum cholesterol and TG were measured using an automated system Hitachi 912 analyzer using an enzymatic method. Serum HDL and LDL were measured using an automated system Cobas C 311/501 analyzer using an enzymatic method.
- Chemerin was measured by a competitive immunoenzymatic method with the commer-
cially available ELISA kits, human chemerin quantikine ELISA kit, supplied by R&D Systems, Inc (14).

– The CRP levels were determined using a turbidimetric immunoassay (Roche Modular Analytics P800; Roche Diagnostics, Indianapolis, IN).

– CEA and CA 19-9 were performed using commercial radioimmunoassay kits (CIS Bio International, France).

**Statistical analysis**

The results were expressed as mean ± standard deviation. The statistical difference between groups was analyzed using Student’s t test. Pearson’s correlation analysis was performed to determine the relationships between variables. The results were considered significant at $P<0.05$. ROC curves were constructed to assess reliability of the new marker in detection of CRC lesions. Sensitivity and specificity were calculated in relation to the best cut-off value obtained from the curve. The statistical calculations were done using Statistical Package for the Social Sciences version 15 software, while the presentations were performed using Microsoft Excel 2007.

**Results**

Table I shows the anthropometric measurements, biochemical parameters, serum adipokine chemerin, CRP, CEA and CA 19-9 levels in the group of patients with CRC (32 subjects) compared with the control group (20 subjects). No significant differences have been observed in age, gender, BMI, FBS, cholesterol, triglycerides, HDL and LDL means among the patients with CRC and controls. Serum chemerin levels were significantly higher ($p<0.001$) in CRC patients ($377.4 ± 80.3$ ng/mL) compared with controls ($87.8 ± 22.01$ ng/mL). Serum CRP levels were significantly higher ($p<0.001$) in CRC patients ($218.48 ± 64.8$ nmol/L) compared with the control group ($49.05 ± 34.3$ nmol/L). CEA levels were significantly higher ($p<0.001$) in CRC (15.59 ± 5.63 ng/mL) compared with controls (1.77 ± 0.47 ng/mL) and CA 19-9 levels were significantly higher ($p<0.001$) in CRC patients (130.39 ± 42.7 U/mL) compared with the control group (20.58 ± 7.6 U/mL).

**Table II** illustrates the correlation between the different studied parameters in patients with CRC. There was a significant positive correlation between serum chemerin levels and CRP ($r=0.98$, $p<0.001$). A significant positive correlation was found between chemerin and CEA levels in patients with CRC ($r=0.95$, $P<0.001$). There was a significant positive correlation between serum chemerin levels and CA 19-9 in CRC patients ($r=0.97$, $p<0.001$).

**Figure 2** illustrates serum chemerin levels at different TNM stages of CRC.

Table II Correlation between chemerin and other studied parameters in the group of CRC patients.

|                      | r     | p-value |
|----------------------|-------|---------|
| Chemerin and CRP     | 0.98  | < 0.001 |
| Chemerin and CEA     | 0.95  | < 0.001 |
| Chemerin and CA 19-9 | 0.97  | < 0.001 |

Serum chemerin levels were significantly higher in advanced stage patients than those of early stage patients ($p<0.05$) [stage I (275.2±58.7 ng/mL), stage III (395.8±103.6 ng/mL), stage IV (420.5±115.3 ng/mL)].
stage II (365±34.6 ng/mL), stage III (407.4±21.8 ng/mL), stage IV (462.3±45.6 ng/mL).

To assess the performance of serum chemerin as a marker, ROC curves were used to calculate the sensitivity of this marker in separating CRC patients from healthy controls. As shown in Figure 2, an area under the curve (AUC) value for serum chemerin reached 1.0. With a cut-off value of 161.5 ng/mL, serum chemerin has a sensitivity of 100%, a specificity of 100% and $p<0.0001$. These results indicated that serum chemerin is a valuable biomarker for CRC diagnosis.

Discussion

The association of colorectal cancer with the alteration of adipokines in blood has not been fully elucidated. Obesity is linked significantly to adipose tissue dysfunction, and obesity-induced inflammation is thought to be an important link between obesity and colorectal cancer (15). Chemerin is a novel member of adipokines that plays important roles in regulating angiogenesis, cell proliferation and migration, inflammation, chemotaxis, glucose, and lipid metabolism (16). Although the dysregulated expression of chemerin in the tumor tissues has been reported, the results are inconsistent. A probable explanation for these inconsistencies is that the expression of chemerin may vary in different types of cancers, which is a common phenomenon in tumor biology (17). In our study, we demonstrated that the serum chemerin level was higher in the CRC patients than in the control subjects. The same results were observed by Erdogan et al. (18) who reported that higher levels of circulating chemerin, CRP, fibrinogen levels, and ESR values are associated with an increased risk of developing CRC. They reported that inflammation is
Cytokine regulation of human CRC is not clearly understood. The systemic and local cytokine environment may modulate the immunogenicity of colorectal cancer cells and affect antitumor immune function of tumor-infiltrating lymphocytes. Focusing on individual cytokines has generated evidence that proinflammatory cytokines and antiinflammatory cytokines may have a complex role in gastrointestinal carcinogenesis (28).

Today, inflammation is known to be a hallmark of cancer. Chronic inflammation is associated with an increase in cancer risk (29). If the cell proliferation occurs in an environment which is rich in growth factors, inflammatory cells, DNA damage-promoting agents, and activated stroma, it increases neoplastic risk (30). The C-reactive protein predicts reduced survival in gastrointestinal cancer patients and is a well-recognized marker of inflammation (31). Increased CRP concentration has been shown to be a strong independent prognostic factor of CRC (32). In our study, the serum CRP level was significantly higher in CRC patients than control subjects, and it was higher with the advancing TNM classification. There was a positive significant correlation between chemerin and CRP. Our findings are in agreement with the results of several previous studies (33, 21). Erdogan et al. (21) reported that chemerin constitutes an interesting candidate as an inflammatory marker.

An ideal diagnostic biomarker should have high disease sensitivity and specificity and provide a cut-off value with minimal overlap between normal and disease states. In view of that, serum chemerin in this study was revealed as an excellent diagnostic biomarker in discriminating CRC patients from healthy controls.

In the current study, the area under curve (AUC) value of serum chemerin was 1.00, with 100% sensitivity and specificity, and diagnostic accuracy at a cut-off value of ≥161.5.

Xu et al. (24) assessed the performance of serum chemerin as a marker in separating NSCLC patients from healthy controls. They reported that at a cut-off value of 1500 pg/mL, serum chemerin has a sensitivity of 62.4%, and a specificity of 67.5%. The combined diagnostic value of chemerin and CEA in NSCLC was further detected. The results showed that the combined detection of these two indices had a sensitivity of 78.3% and a specificity of 84.2%. The combination of chemerin and CEA produced better sensitivity and specificity than chemerin and CEA alone. In another study, ROC curve analysis revealed that serum chemerin has 100% sensitivity and 100% specificity with an area under the curve (AUC) of 1.00 in detecting early stage oral squamous cell carcinoma (OSCC) at a cut-off value of 307 ng/mL (34).

In conclusion, our findings suggest that the adipokine chemerin may have a potential role in the development of CRC and may be a novel and promising biomarker of colorectal cancer and stage progression.
Financial support and sponsorship
Nil.

Authors’ Contributions
MMA contributed in the conception and design of the work, coordinated and carried out all experiments, performed the statistical analysis, participated in manuscript preparation, revised the draft, approved the final version of the manuscript, and agreed to all aspects of the work. PhLM contributed in the conception of the work, provided assistance for all experiments, revised the draft, approved the final version of the manuscript, and agreed to all aspects of the work. NMN contributed in the conception and design of the work, collected samples from patients, prepared the manuscript and revised the draft, approved the final version of the manuscript, and agreed to all aspects of the work.

Conflict of interest statement
The authors stated that they have no conflicts of interest regarding the publication of this article.
20. Zhang J, Jin HC, Zhu AK, Ying RC, Wei W, Zhang FJ. Prognostic significance of plasma chemerin levels in patients with gastric cancer. Peptides 2014; 61: 7–11.

21. Xu CH, Yang Y, Wang YC, Yan J, Qian LH. Prognostic significance of serum chemerin levels in patients with non-small cell lung cancer. Oncotarget 2017; 8(14): 22485–9.

22. Wang N, Wang QJ, Feng YY, Shang W, Cai M. Overexpression of chemerin was associated with tumor angiogenesis and poor clinical outcome in squamous cell carcinoma of the oral tongue. Clin Oral Investig 2014; 18: 997–1004.

23. Kumar JD, Kandola S, Tiszlavicz L, Reisz Z, Dockray GJ, Varro A. The role of chemerin and ChemR23 in stimulating the invasion of squamous oesophageal cancer cells. Br J Cancer 2016; 10: 114(10): 1152–9.

24. Pachynski RK, Zabel BA, Kohrt HE, Tejeda NM, Monnier J, Swanson CD, Holzer AK, Sperinde GV, Edalati A, Hadeiba HA, Alizadeh AA, Butcher EC. The chemoattractant chemerin suppresses melanoma by recruiting natural killer cell antitumor defenses. J Exp Med 2012; 209(8): 1427–35.

25. Lin W, Chen YL, Jiang L, Chen JK. Reduced expression of chemerin is associated with a poor prognosis and a lowered infiltration of both dendritic cells and natural killer cells in human hepatocellular carcinoma. Clin Lab 2011; 57: 879–85.

26. Lin Y, Yang X, Liu W, Li B, Yin W, Shi Y, He R. Chemerin has a protective role in hepatocellular carcinoma by inhibiting the expression of IL-6 and GM-CSF and MDSC accumulation. Oncogene 2017; 36: 3599–608; doi:10.1038/onc.2016.516.

27. Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 2004; 21: 137–48.

28. Dalerba P, Maccalli C, Casati C, Castelli C, Parmiani G. Immunology and immunotherapy of colorectal cancer. Crit Rev Oncol Hematol 2003; 46(1): 33–57.

29. Aggarwal BB, Gehlot P. Inflammation and cancer: how friendly is the relationship for cancer patients? Curr Opin Pharmacol 2009; 9: 351–69.

30. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002; 420: 860–7.

31. Cahlin C, Lonroth C, Arvidsson A, Nordgren S, Lundholm K. Growth associated proteins in tumor cells and stroma related to disease progression of colon cancer accounting for tumor tissue PGE2 content. Int J Oncol 2008; 32(4): 909–18.

32. Tomašević R, Milosavljević T, Stojanović D, Gluvić Z, Dugalić P, Ilić I, Vidaković R. Predictive value of carcinoembryonic and carbohydrate antigen 19-9 related to some clinical, endoscopic and histological colorectal cancer characteristics. J Med Biochem 2016; 35: 324–32.

33. Swede H, Hajduk AM, Sharma J, Rawal S, Rasool H, Vella AT, Tobet RE, Stevens RG. Baseline serum C-reactive protein and death from colorectal cancer in the NHANES III cohort. Int J Cancer 2014; 134: 1862–70.

34. Ghallab NA, Shaker OG. Serum and salivary levels of chemerin and MMP-9 in oral squamous cell carcinoma and oral premalignant lesions. Clin Oral Investig 2017; 21: 937–47.

Received: October 20, 2017
Accepted: December 19, 2017